D. Trist

发表

M. Corsi, D. Trist, 1999, Current protocols in pharmacology.

Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder

S. Palea, M. Corsi, W. Artibani, 1998, British journal of pharmacology.

Failure of the putative neuropeptide Y antagonists, benextramine and PYX‐2, to inhibit Y2 receptors in rat isolated prostatic vas deferens

J. Rimland, S. Palea, M. Corsi, 1995, British journal of pharmacology.

In‐vivo Binding of (+)‐[3H]PN 200–110 to Peripheral Tissues and Brain of Spontaneously Hypertensive Rats: Effect of Lacidipine

G. Gaviraghi, A. Cagnotto, T. Mennini, 1993, The Journal of pharmacy and pharmacology.

Analysis of the CCKB receptor antagonism of virginiamycin in guinea‐pig ileum longitudinal myenteric plexus

G. Gaviraghi, M. Corsi, C. Pietra, 1993, British journal of pharmacology.

Pharmacological analysis of 5‐hydroxytryptamine effects on electrically stimulated human isolated urinary bladder

M. Corsi, W. Artibani, C. Pietra, 1991, British journal of pharmacology.

Estimation of the Relative Potency of Two Glycine Antagonists on NMDA‐induced Depolarizations in BRSC and ARCS

M. Corsi, D. Trist, L. Bettelini, 1997, Annals of the New York Academy of Sciences.

Melatonin, a hormone monitorable in vivo by voltammetry?

F. Crespi, D. Trist, E. Ratti, 1994, The Analyst.

The Apparent Declining Efficiency of Drug Discovery

L. D. Ros, D. Trist, E. Ratti, 2007 .

Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis.

S. Palea, W. Artibani, E. Ostardo, 1993, The Journal of urology.

Antioxidant Dihydropyridines, A New and Comprehensive Therapy for Free Radical-Induced Cardiovascular Diseases

G. Gaviraghi, A. Pastorino, D. Trist, 1997 .

Coexpression with potassium channel subunits used to clone the Y2 receptor for neuropeptide Y.

R. North, J. Rimland, D. Trist, 1996, Molecular Pharmacology.

IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF GV150526, A NOVEL GLYCINE ANTAGONIST AS A POTENT NEUROPROTECTIVE AGENT

G. Gaviraghi, A. Reggiani, D. Trist, 1998 .

The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects

D. Trist, E. Ratti, P. Beardsley, 2002, Behavioural pharmacology.

Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.

A. Capelli, F. Blaney, S. Provera, 2008, Journal of medicinal chemistry.

Synthesis and structure-activity relationship of new 1,5-dialkyl-1,5-benzodiazepines as cholecystokinin-2 receptor antagonists.

G. Tedesco, A. Reggiani, R. Barnaby, 2011, Bioorganic & medicinal chemistry.

Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.

A. Capelli, G. Tedesco, G. Gaviraghi, 2000, Journal of medicinal chemistry.

Synthesis and structure-activity relationship of new 1,5 benzodiazepine CCK-B antagonists

G. Tedesco, G. Gaviraghi, A. Reggiani, 1996 .

Central Cholecystokinin Receptors: Opportunity for Drug Discovery

G. Gaviraghi, M. Marien, D. Trist, 1992 .

EFFICACY OF VESTIPITANT IN PRIMARY INSOMNIA

H. Danker-Hopfe, L. Squassante, E. Merlo-Pich, 2013 .

Mechanisms of Non-Competitive Antagonism and Co-Agonism

M. Corsi, D. Trist, 2000 .

Effects of Cholecystokinin Peptides and GV 150013, a Selective CholecystokininB Receptor Antagonist, on Electrically Evoked Endogenous GABA Release from Rat Cortical Slices

L. Ferraro, A. Reggiani, L. Beani, 1999, Journal of neurochemistry.

Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.

S. Melotto, M. Corsi, D. Montanari, 2011, Journal of medicinal chemistry.

Protective effect of GV150526A on the glutamate-induced changes in basal and electrically-stimulated cytosolic Ca++ in primary cultured cerebral cortical cells

A. Reggiani, L. Beani, T. Antonelli, 1998, Neurochemistry International.

Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.

S. Melotto, M. Corsi, D. Montanari, 2009, Journal of medicinal chemistry.

Discrimination by benextramine between the NPY‐Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein

J. Rimland, S. Palea, M. Corsi, 1995, British journal of pharmacology.

Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists

D. Trist, E. Ratti, A. Bye, 2013, Journal of receptor and signal transduction research.

Different Levels of Receptor Expression as a New Procedure to Estimate Agonist Affinity Constant

F. Ferraguti, C. Corti, M. Corsi, 1997, Annals of the New York Academy of Sciences.

Spontaneous preference for ethanol in naive rats is influenced by cholecystokinin A receptor antagonism.

G. Gaviraghi, M. Corsi, F. Crespi, 1997, Alcohol.

Novel glycine antagonists as potent neuroprotective agents

G. Gaviraghi, A. Reggiani, D. Trist, 1997 .

Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications.

D. Trist, D.G Trist, 2000, Pharmaceutica acta Helvetiae.

NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson’s disease patients

A. Kingsbury, N. Bowery, D. Trist, 1999, Neuropharmacology.

Evidence for two cholecystokinin receptors mediating the contraction of the guinea pig isolated ileum longitudinal muscle myenteric plexus.

G. Gaviraghi, C. Pietra, D. Trist, 1992, The Journal of pharmacology and experimental therapeutics.

Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site.

A. Capelli, G. Tedesco, G. Gaviraghi, 1997, Journal of medicinal chemistry.

Discrimination bybenextramine between theNPY-Y1receptor subtypes present inrabbit isolated vas deferens andsaphenous vein

J. Rimland, M. Corsi, D. Trist, 1995 .

[3H]MK-801 binding and the mRNA for the NMDAR1 subunit of the NMDA receptor are differentially distributed in human and rat forebrain.

D G Trist, N. Bowery, M. Mugnaini, 1998, Brain research. Molecular brain research.

Differential Effects of the CRF-R1 Antagonist GSK876008 on Fear-Potentiated, Light- and CRF-Enhanced Startle Suggest Preferential Involvement in Sustained versus Phasic Threat Responses

M. Davis, D. Walker, M. Corsi, 2008, Neuropsychopharmacology.

Simultaneous, selective detection of catecholaminergic and indolaminergic signals using cyclic voltammetry with treated micro-sensor

Francesco Crespi, F. Crespi, D. Trist, 1995, Journal of Neuroscience Methods.

Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists.

C. Chiamulera, A. Capelli, F. Ferraguti, 2003, Bioorganic & medicinal chemistry.

A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial

D. Luckenbaugh, D. Charney, C. Zarate, 2011, European Neuropsychopharmacology.

Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils

Michael Davis, K. Ressler, M. Corsi, 2009, Behavioural pharmacology.

Further studies on the effects of selective neurokinin agonists upon the activation of micturition reflex in rats. Evidence for a dual NK-1 receptor mediated excitatory and inhibitory activity

G. Gaviraghi, S. Palea, C. Pietra, 1993, Neuropeptides.

Carbon fibre micro-electrodes for concomitant in vivo electrophysiological and voltammetric measurements: no reciprocal influences

Francesco Crespi, F. Crespi, D. Trist, 1995, Neuroscience Letters.

N-terminal splice variants of the NMDAR1 glutamate receptor subunit: differential expression in human and monkey brain

N. Bowery, D. Trist, B. Bunnemann, 1998, Neuroscience Letters.

Co-agonism in drug-receptor interaction: illustrated by the NMDA receptors.

M. Corsi, D. Trist, P. Fina, 1996, Trends in pharmacological sciences.

In memory of Norman Bowery (1944–2016)

T. Kenakin, T. Blackburn, D. Trist, 2017, Current opinion in pharmacology.

Continuing evolution of the drug discovery process in the pharmaceutical industry

D. Trist, E. Ratti, 2001 .

Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A.

A. Reggiani, F. Belardetti, M. Corsi, 1999, The Journal of pharmacology and experimental therapeutics.

Effects of desmethylimipramine and diphenylpropene derivatives on synthesis of rat brain lipids in vivo.

D. Trist, T. J. Rising, P. Johnson, 1973, Life Science.

Pharmacological analysis of carboxyphenylglycines at metabotropic glutamate receptors.

F. Ferraguti, M. Mugnaini, D. Trist, 1994, European journal of pharmacology.

Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder

K. Krishnan, L. Squassante, P. Bettica, 2011, Journal of clinical psychopharmacology.

Regionally different N‐methyl‐D‐aspartate receptors distinguished by ligand binding and quantitative autoradiography of [3H]‐CGP 39653 in rat brain

N. Bowery, M. Mugnaini, D. Trist, 1996, British journal of pharmacology.

Editorial overview: Neurosciences: Clinical pharmacology today in neuroscience drug discovery

D. Trist, A. Bye, 2014 .

GV 196771A, a New Glycine Site Antagonist of the NMDA Receptor with Potent Antihyperalgesic Activity

M. Corsi, M. Mugnaini, D. Trist, 2003 .

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

M. Fava, E. Rabiner, P. Bettica, 2013, Journal of psychopharmacology.

GV 150526A, 7-Cl-kynurenic acid and HA 966 antagonize the glycine enhancement of N-methyl-D-aspartate-induced [3H]noradrenaline and [3H]dopamine release.

L. Mancini, A. Reggiani, T. Mennini, 1997, European journal of pharmacology.

Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.

H. Danker-Hopfe, L. Squassante, E. Merlo-Pich, 2013, Sleep.

The Effects of Demethylimipramine and some Diphenylpropene Derivatives on Rat Brain Lipid Biosynthesis in vivo

D. Trist, T. J. Rising, Peter C. Johnson, 1973 .

The continuing evolution of the drug discovery process in the pharmaceutical industry.

D. Trist, E. Ratti, E Ratti, 2001, Farmaco.

Competitive Antagonism by Phenylglycine Derivatives at Type 1 Metabotropic Glutamate Receptors

F. Ferraguti, H. Eistetter, D. Trist, 1994, Molecular and Cellular Neuroscience.

Scientific process, pharmacology and drug discovery.

D. Trist, David G Trist, 2011, Current opinion in pharmacology.

ADP beta S induces contraction of the human isolated urinary bladder through a purinoceptor subtype different from P2X and P2Y.

G. Gaviraghi, S. Palea, M. Corsi, 1994, The Journal of pharmacology and experimental therapeutics.

Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats.

G. Gaviraghi, T. Seccia, D. Trist, 1999, Blood pressure.

Clinical pharmacology in neuroscience drug discovery: quo vadis?

A. Cohen, D. Trist, A. Bye, 2014, Current opinion in pharmacology.

Editorial.

Michal Williams, D. Trist, 2019, Current opinion in pharmacology.